Concepedia

Publication | Open Access

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma

DOIFull Paper Access

66

Citations

40

References

2012

Year

H-S. Shiah, Cheng‐Yu Chen, Chia‐Yen Dai, Chin‐Fu Hsiao, Yenn‐Jiang Lin, Wu‐Chou Su, Ji Yoon Chang, Jacqueline Whang‐Peng, P. W. Lin, Jian Huang,
Alimentary Pharmacology & Therapeutics

Abstract

The recommended everolimus dosing schedule for future hepatocellular carcinoma studies is 7.5 mg daily. Prophylactic anti-viral therapy should be mandatory for HBsAg-seropositive patients (ClinicalTrials.gov NCT00390195).

References

YearCitations

Page 1